Scinovex
review Open AccessTop 1% cited

Aurora Kinase Inhibitors: Current Status and Outlook

Frontiers in Oncology · 2015 · Vol. 5 · pp. 278–278
Vassilios BavetsiasSpiros Linardopoulos

Abstract

The Aurora kinase family comprises of cell cycle-regulated serine/threonine kinases important for mitosis. Their activity and protein expression are cell cycle regulated, peaking during mitosis to orchestrate important mitotic processes including centrosome maturation, chromosome alignment, chromosome segregation, and cytokinesis. In humans, the Aurora kinase family consists of three members; Aurora-A, Aurora-B, and Aurora-C, which each share a conserved C-terminal catalytic domain but differ in their sub-cellular localization, substrate specificity, and function during mitosis. In addition, Aurora-A and Aurora-B have been found to be overexpressed in a wide variety of human tumors. These observations led to a number of programs among academic and pharmaceutical organizations to discovering small molecule Aurora kinase inhibitors as anti-cancer drugs. This review will summarize the known Aurora kinase inhibitors currently in the clinic, and discuss the current and future directions.

Microtubule and mitosis dynamicsNeuroblastoma Research and TreatmentsCancer-related Molecular PathwaysCurrent (fluid)MedicineKinaseAurora A kinaseCancer researchOncologyInternal medicineBiologyCell biologyCancer

Funding

  • Cancer Research UK
  • Breakthrough Breast Cancer
Citations
281
FWCI
12.43
field-weighted impact
References
95
Percentile
99%
vs. same field & year
Citations per year
Cited by
Aurora kinases: novel therapy targets in cancers
Oncotarget · 2017 · 393 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.